Sero-biomarkers for Predicting Microvascular Invasion in Hepatocellular Carcinoma Before Liver Resection

Y.-Q. Yu,Y. Jin,J.-L. Zhou,J.-J. Yang,C.-M. Qian,X.-X. Zhang,D.-E. Zhou,L. Wang,S.-Y. Peng,J.-T. Li
DOI: https://doi.org/10.1016/j.hpb.2016.02.482
IF: 3.842
2016-01-01
HPB
Abstract:Introduction: Microvascular invasion (MVI) of hepatocellular carcinoma (HCC) is a major risk factor for early recurrence and poor survival after curative surgical therapies. However, MVI can only be diagnosed by pathological examination following resection. The purpose of this study is to identify sero-biomarkers for predicting MVI in HCC preoperatively to help facilitate treatment decisions. Methods: A serological-proteomic approach was employed to identify antigens that are either with corresponding antibody responses in the serum from MVI (+) HCC or that from MVI (-). The lysate of HCC cells was separated by 2-dimensional electrophoresis followed by blotting with sera from 5 MVI (+/−) patients, respectively. Discrepant spots were visualized and identified by mass spectrometry. The sero-antibodies against MVI antigens were detected by ELISA and analyzed. Results: Serum from MVI (+) and MVI (−) patients was able to recognize MVI-related antigens from the lysate of HCC cell line. Six spots were repeatedly seen in either the blot with MVI (+) sera or MVI (−), but not both. They were identified as HSP 70, HSP 90, alpha-enolase (Eno-1), Annexin A2, glutathione synthetase and beta-actin. The titers of anti-Eno-1 antibodies were significantly lower in MVI (-) than those in MVI (+). The titers of anti-HSP 70 antibodies were inverse. Conclusion: Sero-antibodies against Eno-1 and HSP 70 are potential biomarkers for predicting MVI in HCC prior to surgical resection. Eno-1 and HSP 70 as well as their sero-antibodies should be further investigated as potential therapeutic targets.
What problem does this paper attempt to address?